Rigel Pharmaceuticals Grants Inducement Awards to New Employees

Rigel Pharmaceuticals, a leading biotechnology company focused on hematologic disorders and cancer therapies, has announced the granting of inducement awards to new employees. The awards were approved by Rigel’s Compensation Committee and are in accordance with NASDAQ Listing Rule 5635(c)(4), which allows companies to grant awards as an inducement for employees joining the organization.

A total of 285,800 stock options have been granted to seven non-executive employees. These options will vest over a four-year period, with a one-year cliff. The awards are part of Rigel’s commitment to attracting and retaining top talent in order to advance its mission of developing novel therapies that significantly improve patients’ lives.

Rigel Pharmaceuticals, founded in 1996 and based in South San Francisco, California, is dedicated to discovering and providing innovative treatments for hematologic disorders and cancer. The company’s focus on research and development has resulted in a pipeline of potential products that hold promise for patients in need.

Investors and media contacts can find more information about Rigel Pharmaceuticals, including its marketed products and pipeline, on the company’s website at www.rigel.com. For investor inquiries, please contact Rigel Pharmaceuticals directly, and for media inquiries, please reach out to David Rosen at Argot Partners.

Rigel’s commitment to attracting and retaining talented individuals through inducement awards demonstrates its dedication to advancing medical science and improving patient outcomes. With its ongoing research and development efforts, Rigel Pharmaceuticals continues to make significant contributions to the field of biotechnology.